TORONTO, Sept. 28, 2017 /CNW/ -- Ehave, Inc. (OTCQB:
EHVVF), a healthcare company dedicated to empowering the mental
health community with next-generation digital solutions, today
announced publication of a new CEO letter to the Company's
shareholders, providing an update on corporate developments and
business strategy. As outlined in the letter, Ehave has established
and is executing on key partnerships that allow the company to
generate revenue while demonstrating its utility for mental health
researchers, pharmaceutical companies and clinicians, setting Ehave
on a strong growth trajectory. Interested parties can access the
full letter on the Company's website at:
https://www.ehave.com/about/shareholder-letter.
"Ehave has made a great deal of strategic and tactical progress
this year toward fulfilling our vision to transform mental
healthcare, and are excited to provide this context for our
announcements" stated Prateek
Dwivedi, President and CEO of Ehave. "Since our last update,
we've established and expanded the commitments to our mental health
(Multi Health Systems) and therapeutic (MedReleaf TSX: LEAF)
partners, and entered into new partnerships to expand our market
verticals to include the pharmaceutical industry (Aequus TSX-V:
AQS). Meanwhile, we are preparing for our next set of trials of our
new video games for assessment & remediation of ADD/ADHD
developed in collaboration with The Hospital for Sick Children in
Toronto. Separately and together,
these partnerships will demonstrate the versatility and depth of
our platform, which will drive value going forward."
About Ehave, Inc.
Ehave is empowering the mental
healthcare community with a next-generation of data-rich tools
designed to improve patient management, diagnosis and treatment.
With Ehave Connect, Ehave's mental health informatics platform,
clinicians can make objective, data-driven decisions while keeping
patients informed and engaged throughout their mental healthcare
journey. Ehave Connect offers a powerful set of core features that
integrate with a growing selection of tools and applications
developed by Ehave and its leading partners, including Multi-Health
Systems ("MHS"), a leading publisher of psychological assessments.
Ehave is initially focused on improving the standard of care in
attention deficit hyperactivity disorder ("ADHD"), through its
collaboration with the Hospital for Sick Children ("SickKids").
Ehave Connect is also being utilized to advance the validation and
optimization of medical cannabis, through its collaboration with
MedReleaf. For more information, visit
https://www.ehave.com/.
Contacts
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
(212) 375-2664
jdrumm@tiberend.com
Janine McCargo (Media)
646-604-5150
jmccargo@tiberend.com
View original
content:http://www.prnewswire.com/news-releases/ehave-highlights-recent-developments-and-corporate-strategy-in-updated-letter-to-shareholders-300527249.html
SOURCE Ehave, Inc.
